Cover Image
Market Research Report

Europe Exosome Diagnostic and Therapeutic Market Forecast 2019-2027

Published by Inkwood Research Product code 837248
Published Content info 78 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Exosome Diagnostic and Therapeutic Market Forecast 2019-2027
Published: May 13, 2019 Content info: 78 Pages
Description

KEY FINDINGS

The exosomes are cell-derived particles that are secreted upon the fusion of external vesicles with the plasma membrane. The global exosome diagnostic and therapeutic market by the Europe region was valued at $XX million in 2018 and is expected to capture $XX million revenue by the end of 2027 with a CAGR of 27.76% during the forecast period of 2019-2027.

MARKET INSIGHTS

The European exosome diagnostic and therapeutic market is in its infantile phase, and it had stood as the second leading market in the global exosome diagnostic and therapeutic market in 2018. In Europe, the rising prevalence of chronic diseases like that of cancer, cardiovascular, and other communicable diseases augmented with proliferated population and lifestyle deviations in the region has further driven the market growth.

COMPETITIVE INSIGHTS

System Biosciences (SBI), HansaBioMed Life Sciences Ltd. (acquired by Lonza), BioCat GmbH, Nanosomix Inc., Hitachi Chemical Diagnostics, Inc., Thermo Fisher Scientific Inc., Exosome Diagnostics Inc., Codiak BioSciences, Qiagen N.V., Aethlon Medical, Inc., Malvern Instruments Ltd., EVOX Therapeutics Ltd., Capricor Therapeutics, Inc., MBL International Corporation, and Sistemic Ltd. are the major companies operating in the market, which have been exhaustively profiled in the report.

Table of Contents
Product Code: 24962

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. DIAGNOSTIC IS THE MAJORLY USED APPLICATION
    • 3.2.2. SOFTWARE SEGMENT IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
    • 3.2.3. CANCER INSTITUTES HOLD THE LARGEST MARKET SHARE IN TERMS OF END-USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASE IN PERVASIVENESS OF CANCER
    • 4.2.2. RISING GOVERNMENT AND NON GOVERNMENT INITIATIVES
    • 4.2.3. ADVANCEMENT IN TECHNOLOGY
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. CHALLENGES FACED IN THE USAGE OF EXOSOME
    • 4.3.2. STRINGENT REGULATION
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASE IN ADOPTION OF INNOVATIVE AND ADVANCED EXOSOME DIAGNOSTIC AND THERAPEUTIC PROCEDURES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LOW AWARENESS IN THE DEVELOPING COUNTRIES

5. MARKET BY APPLICATION

  • 5.1. DIAGNOSTIC
  • 5.2. THERAPEUTIC

6. MARKET BY PRODUCT

  • 6.1. INSTRUMENT
  • 6.2. REAGENT
  • 6.3. SOFTWARE

7. MARKET BY END-USER

  • 7.1. CANCER INSTITUTE
  • 7.2. HOSPITAL
  • 7.3. DIAGNOSTIC CENTER
  • 7.4. OTHER END-USER

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCES MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. THREAT OF COMPETITIVE RIVALRY
  • 8.2. EXOSOME ETYMOLOGY
  • 8.3. PATENT ANALYSIS
  • 8.4. COMPONENTS OF EXOSOME
  • 8.5. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. EUROPE
    • 9.1.1. GERMANY
    • 9.1.2. FRANCE
    • 9.1.3. THE UNITED KINGDOM
    • 9.1.4. ITALY
    • 9.1.5. SPAIN
    • 9.1.6. REST OF EUROPE

10. COMPETITIVE LANDSCAPE

  • 10.1. COMPANY PROFILES
    • 10.1.1. AETHLON MEDICAL, INC.
    • 10.1.2. BIOCAT GMBH
    • 10.1.3. CAPRICOR THERAPEUTICS, INC.
    • 10.1.4. CODIAK BIOSCIENCES
    • 10.1.5. EVOX THERAPEUTICS LTD.
    • 10.1.6. EXOSOME DIAGNOSTICS INC.
    • 10.1.7. HANSABIOMED LIFE SCIENCES LTD. (ACQUIRED BY LONZA)
    • 10.1.8. HITACHI CHEMICAL DIAGNOSTICS, INC.
    • 10.1.9. MALVERN INSTRUMENTS LTD.
    • 10.1.10. MBL INTERNATIONAL CORPORATION
    • 10.1.11. NANOSOMIX INC.
    • 10.1.12. SISTEMIC LTD.
    • 10.1.13. SYSTEM BIOSCIENCES (SBI)
    • 10.1.14. THERMO FISHER SCIENTIFIC INC.
    • 10.1.15. QIAGEN N.V.

TABLES LIST

  • TABLE 1 NOMENCLATURE OF EXOSOME PARTICLES
  • TABLE 2 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • TABLE 3 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 4 EUROPE DIAGNOSTIC MARKET 2019-2027 ($ MILLION)
  • TABLE 5 EUROPE THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE INSTRUMENT MARKET 2019-2027 ($ MILLION)
  • TABLE 8 COMMERCIAL KITS AND REAGENTS EXAMPLES FOR THE ISOLATION OF EXOSOME
  • TABLE 9 EUROPE REAGENT MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE SOFTWARE MARKET 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END-USER 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE CANCER INSTITUTE MARKET 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE HOSPITAL MARKET 2019-2027 ($ MILLION)
  • TABLE 14 EXOSOME ASSOCIATED PROTEIN IN CLINICAL DIAGNOSTICS USAGE
  • TABLE 15 EUROPE DIAGNOSTIC CENTER MARKET 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE OTHER END-USER MARKET 2019-2027 ($ MILLION)
  • TABLE 17 TYPE OF PROTEINS FOUND IN EXOSOMES
  • TABLE 18 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)

FIGURES LIST

  • FIGURE 1 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 3 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC 2019-2027 ($ MILLION)
  • FIGURE 4 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY THERAPEUTIC 2019-2027 ($ MILLION)
  • FIGURE 5 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY PRODUCT 2018 & 2027 (%)
  • FIGURE 6 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY INSTRUMENT 2019-2027 ($ MILLION)
  • FIGURE 7 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REAGENT 2019-2027 ($ MILLION)
  • FIGURE 8 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY SOFTWARE 2019-2027 ($ MILLION)
  • FIGURE 9 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY END-USER 2018 & 2027 (%)
  • FIGURE 10 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY CANCER INSTITUTE 2019-2027 ($ MILLION)
  • FIGURE 11 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY HOSPITAL 2019-2027 ($ MILLION)
  • FIGURE 12 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC CENTER 2019-2027 ($ MILLION)
  • FIGURE 13 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY OTHER END-USER 2019-2027 ($ MILLION)
  • FIGURE 14 PORTER'S FIVE FORCE MODEL
  • FIGURE 15 NUMBER OF PAPERS PUBLISHED ON EXOSOME 2003-2017
  • FIGURE 16 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 17 GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 18 FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 19 THE UNITED KINGDOM EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 20 ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 21 SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 22 REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
Back to Top